Product image of Insuman Comb 30 (Insulin Human (Rdna)) supplied by GNH India

Insuman Comb 30

Active Ingredient:
Insulin Human (Rdna)
Origin:
EU

Insuman Comb 30 (Insulin Human (Rdna))

Insulin Human, the active ingredient in Insuman Comb 30, is an insulin presented as an injectable solution for subcutaneous use. It treats type 1 and type 2 diabetes mellitus by providing both basal and prandial insulin coverage.
GNH India supplies Insuman Comb 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sanofi-Aventis Deutschland Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Insuman Comb 30 is an insulin preparation used to manage blood glucose in diabetes mellitus and related insulin‑deficiency states.

  • Type 1 diabetes mellitus: provides basal and prandial insulin to achieve target glucose levels.
  • Type 2 diabetes mellitus: supplements endogenous insulin to improve glycaemic control.
  • Insulin deficiency states: replaces missing insulin to maintain glucose homeostasis.

How It Works

  • Insulin Human binds to insulin receptors on cell membranes, activating the receptor’s tyrosine kinase activity. This triggers intracellular signaling cascades that increase glucose transporter translocation, enhance cellular glucose uptake, suppress hepatic gluconeogenesis, and promote glycogen synthesis, thereby lowering blood glucose concentrations.

Side Effects

Insuman Comb 30 may cause a range of adverse reactions.

Common Side Effects

  • Hypoglycaemia: low blood glucose episodes, especially if meals are missed.
  • Injection site reactions: redness, swelling, or itching at the injection site.
  • Weight gain: increased adipose tissue due to improved glucose utilization.
  • Lipodystrophy: localized changes in fat tissue with repeated injections.
  • Mild allergic reactions: urticaria or localized rash.
  • Edema: peripheral fluid accumulation.

Serious or Rare Side Effects

  • Severe hypoglycaemia: neurological impairment requiring immediate assistance.
  • Anaphylaxis: systemic allergic reaction with airway compromise.
  • Insulin allergy: generalized rash, bronchospasm, or angio‑edema.
  • Lipohypertrophy: large, painful fatty deposits that affect insulin absorption.
  • Hypokalemia: low serum potassium in rare cases.
  • Acute insulin resistance: unexpected loss of insulin efficacy.

Precautions & Warnings

When using Insuman Comb 30, several safety considerations are recommended.

  • Dose adjustment: tailor the dose based on regular glucose monitoring and clinical response.
  • Renal impairment: monitor closely as reduced clearance may increase hypoglycaemia risk.
  • Hepatic impairment: use with caution; altered metabolism can affect glucose control.
  • Pregnancy: limited safety data; weigh maternal benefits against potential fetal risks.
  • Hypoglycaemia risk: educate patients on recognising and treating low blood glucose.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Insuman Comb 30 can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection.
  • MAO inhibitors: can cause unpredictable glucose fluctuations.
  • Oral contraceptives: may increase insulin requirements.

Moderate Interactions (Monitor Closely)

  • Thiazide diuretics: may raise blood glucose levels.
  • Corticosteroids: can increase insulin needs due to hyperglycaemic effect.
  • ACE inhibitors: may enhance insulin sensitivity, potentially leading to hypoglycaemia.

Frequently Asked Questions

Insuman Comb 30 is a premixed insulin preparation indicated for the management of blood glucose in patients with type 1 diabetes mellitus, type 2 diabetes mellitus, and other insulin‑deficiency conditions. It provides both rapid‑acting and intermediate‑acting insulin components to cover meals and basal needs.

Insulin Human mimics the action of natural human insulin by binding to insulin receptors on muscle, fat, and liver cells. This binding activates intracellular pathways that increase glucose uptake, inhibit hepatic glucose production, and promote storage of glucose as glycogen, thereby lowering circulating blood sugar levels.

The dose of Insuman Comb 30 is individualized. A qualified prescriber determines the total daily units, the timing of injections, and any dose adjustments based on the patient’s blood glucose readings, diet, activity level, and overall clinical response.

The pregnancy category for Insuman Comb 30 is not definitively established. Use during pregnancy or lactation should be considered only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be managed by a healthcare professional experienced in diabetes care.

To order Insuman Comb 30, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and any necessary import documentation.

Insuman Comb 30 is a premixed insulin containing both rapid‑acting and intermediate‑acting components, offering a convenient twice‑daily regimen. Compared with basal‑only insulins, it provides prandial coverage without separate rapid‑acting injections, while offering more predictable absorption than some other premixed formulations.

Store Insuman Comb 30 at 2‑8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the vial. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, as indicated on the label.

Insuman Comb 30 is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. Injections should be given at consistent times each day, and injection sites should be rotated to reduce the risk of lipodystrophy. Patients should follow their prescriber’s instructions for dose and timing.

The most serious risks include severe hypoglycaemia, which can cause confusion, loss of consciousness, or seizures, and systemic allergic reactions such as anaphylaxis. Patients should be educated to recognise early signs of low blood glucose and to seek immediate medical help if a severe reaction occurs.

Insuman Comb 30 should be avoided in individuals with a known hypersensitivity to human insulin or any excipients in the formulation. It is also contraindicated in patients experiencing hypoglycaemia unawareness or those with severe renal or hepatic failure unless closely supervised by a specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Human (Rdna)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT